Therapeutic Strategies for the Clinical Blockade of IL-6/gp130 Signaling

J Clin Invest. 2011 Sep;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1.

Abstract

The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / immunology
  • Cytokine Receptor gp130 / immunology*
  • Humans
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Interleukin-6 / immunology*
  • Neoplasms / immunology
  • Receptors, Interleukin-6 / genetics
  • Receptors, Interleukin-6 / immunology*
  • Signal Transduction / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-6
  • Receptors, Interleukin-6
  • Cytokine Receptor gp130
  • tocilizumab